

23

LKS Faculty of Medicine School of Public Health 香港大學公共衞生學院





Changes in the Population Immunity against SARS-CoV-2 Omicron variants in Hong Kong, 2022-2023 C Wang¹, BJ Cowling^{1,2}, TK Tsang^{1,2}

¹ WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.

² Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology Park, New Territories, Hong Kong.


Background

- As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic progressed, a substantial fraction of HK population was infected during January 2022-February 2023 by Omicron variant.
- The subsequent evolution of population immunity that reflects the additional protection of vaccination and infections is rarely explored.

- Effective protection against SARS-CoV-2 infection that accounted vaccine effective and waning effects of protection increased significantly from 8% to 30% (95% CI: 24-57%) and 10% to 55% (95% CI: 40-80%) for children and adults, respectively. At the end of January 2023, over 60% (median) of the adults gained effective immunity against SARS-CoV-2 infection while only 45% of children had immunity against infection (Figure 3).
- To quantify dynamics of effective population-level immunity against SARS-CoV-2 infection in HK.

Methods

- We developed a deterministic age-structured COVID-19 transmission model [1] with vaccination status and Bayesian inference framework to analyse epidemiological surveillance data from HK including age-specific reported cases, vaccinations, waning pattern of both natural infection- and vaccination-induced immunity.
- We fitted the transmission model to daily reported cases for children, adults and the elderly.
- The transmission rate was estimated based on a random walk model and estimated cases follow a negative binomial process to account for reporting error.
- We estimated age-specific effective protection against SARS-CoV-2 infection and reporting rate over time.







Figure3. Estimated effective protection (median estimates) against SARS-CoV-2 infection by infection, vaccination status and age groups.

- The reporting rate was assumed constant for symptomatic infections and time-varying for asymptomatic infections. We estimated that symptomatic reporting rate for the elderly was the highest among all age groups 56.7% (95% CI: 26.9%, 64.4%).
- Asymptomatic reporting rate increased rapidly after the deployment of mass testing with RAT at the end of January, 2022 and declined gradually, maintaining similar levels

Figure1. Model compartments were expanded to account for 8 vaccination strata, corresponding to first dose, first dose effective, second dose, second dose effective, second dose waning, booster dose, booster dose effective and booster dose waning.

Results

- Between 1 January 2022 to 31 May 2022, 52% (95 credible interval (CI): 25-78%) of the HK population were estimated to have been infected by SARS-CoV-2. Of those, adults aged 18-64 had the highest attack rate (57%, 95% CI: 28-86%) (Figure 2).
- At the end of February 2022, there were around 18,000, 140,000 and 60,000 infections at the peak for 3 age groups, respectively.



thereafter.




Figure3. Estimated timevarying reporting rates for asymptomatic cases for 3 age groups. Solid lines are median estimates whereas shaded areas represent 95% Cis.

Figure2. Model fitting and estimated daily number of infections for 3 age groups. Black dots represent the observed cases, blue lines represent median estimated cases and shaded areas are 95% Cis.

Conclusion

- protection against SARS-CoV-2 Effective infection increased substantially during the fifth wave, resulting in a large proportion of the HK population with hybrid immunity.
- There were a large proportion of children still susceptible to SARS-CoV-2 Omicron infection.
- Future analyses may focus on incorporating two cocirculating Omicron subvariants for more specific immunity patterns.

References

[1] Perez-Guzman PN, Knock E, Imai N, et al. Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England [published correction appears in Nat Commun. 2023 Dec 7;14(1):8099]. Nat Commun. 2023;14(1):4279. Published 2023 Jul 17. doi:10.1038/s41467-023-39661-5